Search

Your search keyword '"Mengozzi, G"' showing total 650 results
Start Over Author "Mengozzi, G"
650 results on '"Mengozzi, G"'

7. Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson's disease patients

Author

Zago E., Dal Molin A., Dimitri G. M., Xumerle L., Pirazzini C., Bacalini M. G., Maturo M. G., Azevedo T., Spasov S., Gomez-Garre P., Perinan M. T., Jesus S., Baldelli L., Sambati L., Calandra Buonaura G., Garagnani P., Provini F., Cortelli P., Mir P., Trenkwalder C., Mollenhauer B., Franceschi C., Lio P., Nardini C., Adarmes-Gomez A., Bartoletti-Stella A., Bhatia K. P., Marta B. -T., Boninsegna C., Broli M., Dolores B. -R., Calandra-Buonaura G., Capellari S., Carrion-Claro M., Cilea R., Clayton R., Molin A. D., De Luca S., De Massis P., Doykov I., Escuela-Martin R., Fabbri G., Gabellini A., Giuliani C., Guaraldi P., Hagg S., Hallqvist J., Halsband C., Heywood W., Houlden H., Huertas I., Jylhava J., Labrador-Espinosa M. A., Licari C., Luchinat C., Macias D., Macri S., Magrinelli F., Rodriguez J. F. M., Massimo D., Mengozzi G., Meoni G., Mignani F., Milazzo M., Mills K., Nassetti S. A., Pedersen N. L., Perinan-Tocino M. T., Ravaioli F., Sala C., Scaglione C. L. M., Schade S., Schreglmann S., Strom S., Tejera-Parrado C., Tenori L., Turano P., Valzania F., Ortega R. V., Williams D., Apollo - University of Cambridge Repository, Zago E., Dal Molin A., Dimitri G.M., Xumerle L., Pirazzini C., Bacalini M.G., Maturo M.G., Azevedo T., Spasov S., Gomez-Garre P., Perinan M.T., Jesus S., Baldelli L., Sambati L., Calandra Buonaura G., Garagnani P., Provini F., Cortelli P., Mir P., Trenkwalder C., Mollenhauer B., Franceschi C., Lio P., Nardini C., Adarmes-Gomez A., Bartoletti-Stella A., Bhatia K.P., Marta B.-T., Boninsegna C., Broli M., Dolores B.-R., Calandra-Buonaura G., Capellari S., Carrion-Claro M., Cilea R., Clayton R., Molin A.D., De Luca S., De Massis P., Doykov I., Escuela-Martin R., Fabbri G., Gabellini A., Giuliani C., Guaraldi P., Hagg S., Hallqvist J., Halsband C., Heywood W., Houlden H., Huertas I., Jylhava J., Labrador-Espinosa M.A., Licari C., Luchinat C., Macias D., Macri S., Magrinelli F., Rodriguez J.F.M., Massimo D., Mengozzi G., Meoni G., Mignani F., Milazzo M., Mills K., Nassetti S.A., Pedersen N.L., Perinan-Tocino M.T., Ravaioli F., Sala C., Scaglione C.L.M., Schade S., Schreglmann S., Strom S., Tejera-Parrado C., Tenori L., Turano P., Valzania F., Ortega R.V., and Williams D.

Subjects
Male, Aging, Molecular biology, Science, Immunology, Article, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Medical research, Humans, Parkinson, 030304 developmental biology, Aged, 0303 health sciences, Multidisciplinary, Biological techniques, Parkinson Disease, Middle Aged, 3. Good health, nervous system diseases, Computational biology and bioinformatics, MicroRNAs, Neurology, ageing, Medicine, Female, 030217 neurology & neurosurgery, Biomarkers
Abstract

Advanced age represents one of the major risk factors for Parkinson's Disease. Recent biomedical studies posit a role for microRNAs, also known to be remodelled during ageing. However, the relationship between microRNA remodelling and ageing in Parkinson's Disease, has not been fully elucidated. Therefore, the aim of the present study is to unravel the relevance of microRNAs as biomarkers of Parkinson's Disease within the ageing framework. We employed Next Generation Sequencing to profile serum microRNAs from samples informative for Parkinson's Disease (recently diagnosed, drug-naïve) and healthy ageing (centenarians) plus healthy controls, age-matched with Parkinson's Disease patients. Potential microRNA candidates markers, emerging from the combination of differential expression and network analyses, were further validated in an independent cohort including both drug-naïve and advanced Parkinson's Disease patients, and healthy siblings of Parkinson's Disease patients at higher genetic risk for developing the disease. While we did not find evidences of microRNAs co-regulated in Parkinson's Disease and ageing, we report that hsa-miR-144-3p is consistently down-regulated in early Parkinson's Disease patients. Moreover, interestingly, functional analysis revealed that hsa-miR-144-3p is involved in the regulation of coagulation, a process known to be altered in Parkinson's Disease. Our results consistently show the down-regulation of hsa-mir144-3p in early Parkinson's Disease, robustly confirmed across a variety of analytical and experimental analyses. These promising results ask for further research to unveil the functional details of the involvement of hsa-mir144-3p in Parkinson's Disease., This work was supported by the Horizon 2020 Framework Programme (Grant number 634821, PROPAG-AGING).

Published
2022

9. Early downregulation of hsa-miR-144-3p in serum from drug-naïve Parkinson’s disease patients

Author

Zago, E., Dal Molin, A., Dimitri, G. M., Xumerle, L., Pirazzini, C., Bacalini, M. G., Maturo, M. G., Azevedo, T., Spasov, S., Gomez-Garre, P., Perinan, M. T., Jesus, S., Baldelli, L., Sambati, L., Calandra-Buonaura, G., Garagnani, P., Provini, F., Cortelli, P., Mir, P., Trenkwalder, C., Mollenhauer, B., Franceschi, C., Lio, P., Nardini, C., Adarmes-Gomez, A., Bartoletti-Stella, A., Bhatia, K. P., Marta, B. -T., Boninsegna, C., Broli, M., Dolores, B. -R., Capellari, S., Carrion-Claro, M., Cilea, R., Clayton, R., Molin, A. D., De Luca, S., De Massis, P., Doykov, I., Escuela-Martin, R., Fabbri, G., Gabellini, A., Giuliani, C., Guaraldi, P., Hagg, S., Hallqvist, J., Halsband, C., Heywood, W., Houlden, H., Huertas, I., Jylhava, J., Labrador-Espinosa, M. A., Licari, C., Luchinat, C., Macias, D., Macri, S., Magrinelli, F., Rodriguez, J. F. M., Massimo, D., Mengozzi, G., Meoni, G., Mignani, F., Milazzo, M., Mills, K., Nassetti, S. A., Pedersen, N. L., Perinan-Tocino, M. T., Ravaioli, F., Sala, C., Scaglione, C. L. M., Schade, S., Schreglmann, S., Strom, S., Tejera-Parrado, C., Tenori, L., Turano, P., Valzania, F., Ortega, R. V., and Williams, D.

Subjects
hsa‑miR‑144‑3p, serum, Parkinson’s disease patients
Published
2022

16. Efficacy of self-monitoring blood glucose as a key component of a chronic care model versus usual care in type 2 diabetes patients treated with oral agents: results of a randomized trial

Author

Musacchio, N, Ciullo, I, Scardapane, M, Giancaterini, A, Pessina, L, Maino, S, Gaiofatto, R, Nicolucci, A, Rossi, M, Valentini, U, Cimino, A, Agosti, B, Zarra, E, Magri, A, Pellegrini, M, Pellarini, L, Sciangula, L, Nappi, F, Ciucci, A, Grassa, B, De Marco, R, Olivo, E, Trevisan, R, Frosio, I, Morlini, C, Corsi, A, Dodesini, A, Grassi, G, Calvi, E, Capello, E, Gramaglia, E, Ramella, V, De Rossi, C, Mengozzi, G, Orsi, E, Lunati, M, Palmieri, E, Resi, V, Grancini, V, Giarratana, L, Ragonese, M, Slongo, R, Scoponi, C, Tonolo, G, Amadori, G, Becciu, A, Canu, L, Cherchi, S, Paciotti, V, Alfidi, P, Babini, A, Ripani, R, Cantelli, R, Rossi, P, Di Cianni, G, Russo, L, Lemmi, P, Sannino, C, Marconi, S, Di Bartolo, P, Pellicano, F, Scolozzi, P, Annese, S, Lorizzo, F, Coppolino, A, Peditto, G, De Feo, M, Piscopo, G, Varriale, A, De Candia, L, Ceci, A, Elia, G, Falzone, G, Schembari, R, Citro, G, Di Mauro, M, D'Urso, C, Caruso, C, Musacchio N., Ciullo I., Scardapane M., Giancaterini A., Pessina L., Maino S., Gaiofatto R., Nicolucci A., Rossi M. C., Valentini U., Cimino A., Agosti B., Zarra E., Magri A., Pellegrini M. A., Pellarini L., Sciangula L., Nappi F., Ciucci A., Grassa B., De Marco R., Olivo E. S., Trevisan R., Frosio I., Morlini C., Corsi A., Dodesini A. R., Grassi G., Calvi E., Capello E., Gramaglia E., Ramella V., De Rossi C., Mengozzi G., Orsi E., Lunati M. E., Palmieri E., Resi V., Grancini V., Giarratana L., Ragonese M., Slongo R., Scoponi C., Tonolo G., Amadori G., Becciu A., Canu L., Cherchi S., Paciotti V., Alfidi P., Babini A., Ripani R., Cantelli R., Rossi P., Di Cianni G., Russo L., Lemmi P., Sannino C., Marconi S., Di Bartolo P., Pellicano F., Scolozzi P., Annese S., Lorizzo F., Coppolino A., Peditto G. C., De Feo M. E., Piscopo G., Varriale A., De Candia L., Ceci A., Elia G., Falzone G., Schembari R., Citro G., Di Mauro M., D'Urso C., Caruso C., Musacchio, N, Ciullo, I, Scardapane, M, Giancaterini, A, Pessina, L, Maino, S, Gaiofatto, R, Nicolucci, A, Rossi, M, Valentini, U, Cimino, A, Agosti, B, Zarra, E, Magri, A, Pellegrini, M, Pellarini, L, Sciangula, L, Nappi, F, Ciucci, A, Grassa, B, De Marco, R, Olivo, E, Trevisan, R, Frosio, I, Morlini, C, Corsi, A, Dodesini, A, Grassi, G, Calvi, E, Capello, E, Gramaglia, E, Ramella, V, De Rossi, C, Mengozzi, G, Orsi, E, Lunati, M, Palmieri, E, Resi, V, Grancini, V, Giarratana, L, Ragonese, M, Slongo, R, Scoponi, C, Tonolo, G, Amadori, G, Becciu, A, Canu, L, Cherchi, S, Paciotti, V, Alfidi, P, Babini, A, Ripani, R, Cantelli, R, Rossi, P, Di Cianni, G, Russo, L, Lemmi, P, Sannino, C, Marconi, S, Di Bartolo, P, Pellicano, F, Scolozzi, P, Annese, S, Lorizzo, F, Coppolino, A, Peditto, G, De Feo, M, Piscopo, G, Varriale, A, De Candia, L, Ceci, A, Elia, G, Falzone, G, Schembari, R, Citro, G, Di Mauro, M, D'Urso, C, Caruso, C, Musacchio N., Ciullo I., Scardapane M., Giancaterini A., Pessina L., Maino S., Gaiofatto R., Nicolucci A., Rossi M. C., Valentini U., Cimino A., Agosti B., Zarra E., Magri A., Pellegrini M. A., Pellarini L., Sciangula L., Nappi F., Ciucci A., Grassa B., De Marco R., Olivo E. S., Trevisan R., Frosio I., Morlini C., Corsi A., Dodesini A. R., Grassi G., Calvi E., Capello E., Gramaglia E., Ramella V., De Rossi C., Mengozzi G., Orsi E., Lunati M. E., Palmieri E., Resi V., Grancini V., Giarratana L., Ragonese M., Slongo R., Scoponi C., Tonolo G., Amadori G., Becciu A., Canu L., Cherchi S., Paciotti V., Alfidi P., Babini A., Ripani R., Cantelli R., Rossi P., Di Cianni G., Russo L., Lemmi P., Sannino C., Marconi S., Di Bartolo P., Pellicano F., Scolozzi P., Annese S., Lorizzo F., Coppolino A., Peditto G. C., De Feo M. E., Piscopo G., Varriale A., De Candia L., Ceci A., Elia G., Falzone G., Schembari R., Citro G., Di Mauro M., D'Urso C., and Caruso C.

Published
2018

18. Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis

Author

Sansoe, G., Aragno, M., Mastrocola, R., Cutrin, J.C., Silvano, S., Mengozzi, G., Smedile, A., Rosina, F., Danni, O., and Rizzetto, M.

Subjects
Ascites -- Research, Ascites -- Properties, Natriuretic peptides -- Research, Biological sciences
Abstract

Neutral endopeptidase degrades atrial natriuretic peptide (ANP) and bradykinin and may generate endothelin-1 from big-endothelin. In advanced cirrhosis, sodium retention is accompanied by elevated plasma ANP levels, and infusion of ANP causes hypotension, but in normal humans increasing the concentration of ANP through the inhibition of neutral endopeptidase, localized in renal proximal tubule cells, causes natriuresis without any arterial pressure drop. The purpose of this study was the assessment of kidney neutral endopeptidase expression and responses to candoxatrilat (a specific inhibitor of this enzyme) in rats with C[Cl.sub.4]-induced cirrhosis. Two groups of control rats (n = 5) were injected with vehicle or 3 mg/kg candoxatrilat. Three groups of cirrhotic rats with ascites (n = 10) received vehicle alone or 3 or 10 mg/kg candoxatrilat. In cirrhotic rats, Western blot analysis revealed a 170% increase in renal neutral endopeptidase protein content (P < 0.03), mainly in the proximal nephron and macula densa, and both candoxatrilat dosages increased plasma ANP levels, urinary volume, and urinary excretion of sodium, ANP, and cGMP compared with vehicle alone (all P < 0.03). Candoxatrilat (10 mg/kg) also reduced tubular solute-free water reabsorption (P < 0.03) in cirrhotic rats, but renal blood flow, arterial pressure, and plasma rehin activity were unaffected. Neutral endopeptidase inhibition has natriuretic and aquaretic actions in cirrhosis without any effect on blood pressure and kidney perfusion due to a significant overexpression of this enzyme in renal cortex. ascites; animal model; atrial natriuretic peptide

Published
2006

21. Neuroendocrine predictors of vasoplegia after cardiopulmonary bypass

Author

Pasero, D., primary, Berton, A. M., additional, Motta, G., additional, Raffaldi, R., additional, Fornaro, G., additional, Costamagna, A., additional, Toscano, A., additional, Filippini, C., additional, Mengozzi, G., additional, Prencipe, N., additional, Zavattaro, M., additional, Settanni, F., additional, Ghigo, E., additional, Brazzi, L., additional, and Benso, A. S., additional

Published
2020
Full Text
View/download PDF

23. Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders

Author

Cavalla, P., primary, Caropreso, P., additional, Limoncelli, S., additional, Bosa, C., additional, Pasanisi, M.B., additional, Schillaci, V., additional, Alteno, A., additional, Costantini, G., additional, Giordana, M.T., additional, Mengozzi, G., additional, and Vercellino, M., additional

Published
2020
Full Text
View/download PDF

24. Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality?

Author

Campion, D., primary, Rizzo, M., additional, Ponzo, P., additional, Risso, A., additional, Giovo, I., additional, Rizzi, F., additional, Roma, M., additional, Caropreso, P., additional, Caviglia, G.P., additional, Colla, L., additional, Biancone, L., additional, Manca, A., additional, Mengozzi, G., additional, Saracco, G.M., additional, and Alessandria, C., additional

Published
2020
Full Text
View/download PDF

36. VIDAS PTH(1-84) ASSAY: Reference limits and comparison with three other third generation PTH assays

Author

Bouchard-Lovighi, G., primary, Veillet, A., additional, Tsoumperi, D., additional, Pages, J., additional, Favre, C., additional, Brossault, L., additional, Dromenq, L., additional, Tessonneau, M., additional, Mougin, B., additional, Priolo, G., additional, Martinasso, G., additional, Mengozzi, G., additional, Lukas, P., additional, and Cavalier, E., additional

Published
2019
Full Text
View/download PDF

41. Haemodynamic modulations in IgA nephropathy

Author

ROCCATELLO, D, MENGOZZI, G, MOSSO, R, GIGLIOLA, G, CACACE, G, POLLONI, R, CESANO, G, PICCIOTTO, G, PARADISI, L, BANCALE, E, PICCOLI, G, SENA, LM, and COPPO, R

Published
1997

49. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders

Author

Guidetti, C Sategna, Solerio, E, Scaglione, N, Aimo, G, and Mengozzi, G

Subjects
Celiac disease -- Complications and side effects -- Development and progression, Gluten -- Health aspects -- Analysis, Comorbidity -- Analysis -- Development and progression -- Complications and side effects, Autoimmune diseases -- Development and progression -- Complications and side effects, Health
Abstract

Abstract Background and aims--Duration of gluten exposure seems to predispose adolescents with coeliac disease to autoimmune diseases. In a retrospective cohort study, we assessed the relationship between autoimmune disorders and [...]

Published
2001

50. Levels of N-terminal pro brain natriuretic peptide are enhanced in people with the uncomplicated metabolic syndrome: a case-cohort analysis of the population-based Casale Monferrato study

Author

Bruno, Graziella, Barutta, Federica, Landi, A, Pinach, Silvia, Caropreso, P, Mengozzi, G, Baldassarre, S, Fragapani, S, Civera, S, Cavallo Perin, P, and Gruden, Gabriella

Subjects
cardiovascular risk, Male, obesity, cardiovascular risk, hypertension, metabolic syndrome, natriuretic peptides, obesity, population-based study, survey, Severity of Illness Index, Body Mass Index, Cohort Studies, Prediabetic State, Natriuretic Peptide, Brain, Prevalence, Humans, survey, Aged, Dyslipidemias, Metabolic Syndrome, Middle Aged, Overweight, Peptide Fragments, Up-Regulation, Cross-Sectional Studies, Italy, population-based study, Case-Control Studies, Obesity, Abdominal, Hypertension, Female, Insulin Resistance, Waist Circumference, natriuretic peptides
Abstract

Both metabolic syndrome (MetS) and N-amino terminal fragment of the prohormone B-type natriuretic peptide (NT-proBNP) confer increased risk of cardiovascular diseases (CVD). We assessed if NT-proBNP levels were greater in people with uncomplicated MetS, who had neither CVD/chronic kidney disease (CKD) nor diabetes, as compared with subjects who met none of the defining criteria of the MetS.A case-cohort study from the non-diabetic population-based Casale Monferrato study was performed, after exclusion of all subjects with established CVD, CKD [estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m(2)], and CRP values ≥3 mg/L. Cases (n = 161) with MetS were compared with all subjects within the cohort (n = 124) who were completely free of any component of the MetS. Serum NT-proBNP was centrally measured by immunoenzymatic assay.NT-proBNP levels were significantly higher in cases than in control subjects [35.4 (15.5-98.2) vs 24.4 (11.7-49.6) pg/mL, p = 0.014]. In logistic regression analysis, compared with NT-proBNP values in the lower quartiles (≤49.64 pg/mL), higher values conferred odds ratio 4.17 (1.30-13.44) of having the MetS, independently of age, sex, microalbuminuria, CRP, eGFR, and central obesity. This association was evident even after the exclusion of hypertensive subjects. Further adjustment for log-HOMA and diastolic blood pressure did not modify the strength of the association, while central obesity was a negative confounder.Compared with people without any component of the MetS, those with uncomplicated MetS, who had neither CVD/CKD nor diabetes, had increased NT-proBNP values, even if they were normotensive and although absolute values were still in the low range. The insulin resistance state did not mediate this association, while central obesity was a negative confounder.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results